Study of JNJ-55920839 to identify transcriptional gene signatures predictive of clinical response, for pharmacodynamic evaluation in participants with systemic lupus erythematosus
Latest Information Update: 21 Oct 2021
At a glance
- Drugs JNJ 55920839 (Primary)
- Indications Systemic lupus erythematosus
- Focus Pharmacodynamics
- 21 Oct 2021 New trial record